AInvest Newsletter
Daily stocks & crypto headlines, free to your inbox
BeOne Medicines Cashes In on Amgen Cancer Drug Royalties in $950mln Pharma Tie-Up
ByAinvest
Monday, Aug 25, 2025 1:22 pm ET1min read
BeOne Medicines has agreed to sell its royalty rights on Amgen's cancer drug Imdelltra for up to $950 million to Royalty Pharma. The upfront payment is $885 million, with the option to sell remaining royalties for up to $65 million. BeOne will share in a portion of the royalty on annual sales above $1.5 billion and maintain rights to other assets under the existing collaboration with Amgen. Imdelltra is a first-in-class immunotherapy approved in the US for patients with extensive-stage small cell lung cancer.
BeOne Medicines Ltd. has agreed to sell its royalty rights on Amgen's cancer drug Imdelltra for up to $950 million to Royalty Pharma. The upfront payment is $885 million, with the option to sell remaining royalties for up to $65 million [1]. BeOne will share in a portion of the royalty on annual sales above $1.5 billion and maintain rights to other assets under the existing collaboration with Amgen [2].Imdelltra, a first-in-class immunotherapy, is approved in the US for patients with extensive-stage small cell lung cancer (ES-SCLC) [3]. The drug received accelerated approval from the FDA in May 2024 and is currently enrolling Phase 3 studies for front-line small cell lung cancer [1].
This transaction provides BeOne with immediate cash to advance its internal pipeline while reducing risks from potential Imdelltra competition. "By monetizing a significant portion of our royalty interest in Imdelltra, we are able to strengthen our balance sheet and unlock substantial value," said John V. Oyler, Co-Founder, Chairman, and CEO of BeOne [2].
The deal also reflects the growing interest in DLL3-targeting therapies, with several large companies exploring the space. Imdelltra's sales reached $215 million in the first half of 2025, and analysts' consensus currently pegs the drug could reach $2.8 billion in sales by 2035 [3].
References:
[1] https://www.nasdaq.com/articles/royalty-pharma-acquires-royalty-interest-imdelltra-beone
[2] https://www.marketscreener.com/news/beone-medicines-announces-imdelltra-royalty-purchase-agreement-for-up-to-950-million-ce7c50dbd081f627
[3] https://www.fiercepharma.com/pharma/beone-bags-885m-royalty-deal-amgen-lung-cancer-drug-imdelltra
Ainvest News articles are AI-generated using advanced large language model (LLM) technology designed to analyze and synthesize publicly available data and news. While AI tools assist in producing initial drafts and insights, all AI generated content published on Ainvest is subject to comprehensive human editorial review before publication. A designated human editor reviews, verifies, and approves each article for factual accuracy, coherence, and compliance with AInvest Fintech Inc’s editorial and disclosure standards.
Despite these review procedures, the information provided may still contain inaccuracies, incomplete data, or time sensitive references due to the inherent limitations of AI generated analysis and evolving changes. The material is provided strictly for informational and educational purposes and does not constitute personalized investment, legal, or financial advice. Readers should independently verify all facts, figures, and statements before making any decision based on this content.
AInvest Fintech Inc. its affiliates, and partners accept no liability or responsibility for any direct or consequential losses arising from reliance on this content. All articles and analyses are subject to revision, update, or removal without prior notice to maintain accuracy and integrity in our publications.
Comments
No comments yet